Acute lymphoblastic leukaemia occurs in both children and adults but its incidence peaks between 2 and 5 years of age. Causation is multifactorial and exogenous or endogenous exposures, genetic susceptibility, and chance have roles. Survival in paediatric acute lymphoblastic leukaemia has improved to roughly 90% in trials with risk stratifi cation by biological features of leukaemic cells and response to treatment, treatment modifi cation based on patients' pharmacodynamics and pharmacogenomics, and improved supportive care. However, innovative approaches are needed to further improve survival while reducing adverse eff ects. Prognosis remains poor in infants and adults. Genome-wide profi ling of germline and leukaemic cell DNA has identifi ed novel submicroscopic structural genetic changes and sequence mutations that contribute to leukaemogenesis, defi ne new disease subtypes, aff ect responsiveness to treatment, and might provide novel prognostic markers and therapeutic targets for personalised medicine.
Introduction
An estimated 6000 new cases (male:female prevalence of roughly 1·3:1) of acute lymphoblastic leukaemia are diagnosed yearly in the USA. 1 Patients are mainly children; roughly 60% of cases occur in people aged younger than 20 years. [2] [3] [4] [5] Survival in childhood acute lymphoblastic leukaemia is approaching 90% (appendix), 4, 6 but treatment in infants (ie, children younger than 12 months) and adults needs improve ment. 5, 7 We review advances in the epidemiology, pathobiology, and clinical management of acute lympho blastic leukaemia.
Epidemiology
Acute lymphoblastic leukaemia, like cancer in general, probably arises from interactions between exogenous or endogenous exposures, genetic (inherited) suscep tibility, and chance (fi gure 1). These factors account for the roughly 1 in 2000 risk of the disease in childhood (0-15 years). The challenge is to identify the relevant exposures and inherited genetic variants and decipher how and when these factors contribute to the multistep natural history of acute lymphoblastic leukaemia from initiation (usually in utero) through the largely covert evolution to overt disease. 8 The rarity of the illness and the existence of biologically distinct subtypes that might not share common causative mechanisms compli cates matters. 12 For example, in infants acute lymphoblastic leukaemia is usually associated with MLL rearrangement, and the remarkably high concor dance rate in monozygotic twins (approaching 100% in those with a single or monochorionic placenta) suggests that leukaemogenesis is largely complete at birth. 9 By contrast, incidence of non-MLL-rearranged B lympho blastic leukaemia peaks between 2 and 5 years and has a concordance rate of 10-15%, suggesting that, although initiation in utero usually occurs, other so-called promotional exposures are probably necessary for dis ease emergence. 9 
Contributing exposures
Exposures and their roles remain contentious. More than 20 candidate exposures that contribute to childhood disease have been identifi ed through epidemiological and case-control studies, 10 but very few of these fi ndings are based on reproducible data or are biologically plausible. Some of these candidate expo sures are of public concern, especially ionising and non-ionising (eg, electromagnetic fi eld) radiation. Ionising radiation is an established causal exposure for childhood acute lymphoblastic leukaemia, as evidenced by the eff ects of the 1945 atomic bombs in Japan 13 and the slightly but signifi cantly increased risks associated with x-ray pelvimetry during pregnancy.
14 Such exposures are no longer relevant, although some scientists argue that background or natural radiation could be important. 15 Exposures to electromagnetic fi elds (eg, via power lines) have been particularly controversial, and concern or confusion might be exacerbated by uncritical news reporting. A meta-analysis 16 suggests that high levels of electromagnetic fi eld radiation (ie, magnetic fl ux densities >0·2 μT) are associated with slightly increased risk, but the reliability of this fi nding is uncertain. To prove that exposure to electromagnetic fi elds never causes acute lymphoblastic leukaemia is impossible, but at most such radiation might be implicated in only a few cases. Furthermore, the likelihood that exposure to electromagnetic fi eld radiation is causal in promotional or latestage leukaemia development is lessened by the absence of any biological mechanism or credible modelling in vitro or in vivo.
Infection was the fi rst suggested causal exposure for childhood acute lymphoblastic leukaemia 17 and remains the strongest candidate. Two specifi c hypotheses have been proposed, are often referred to by their eponymous titles, and are supported by epidemiological data (table 1) . 11, 17, 18 Both postulate that the disease results from an abnormal response to a common infection. The hypotheses diff er in detail but are not mutually exclusive as explanations of rare time-space clusters of leukaemia 19, 25 or acute lymphoblastic leukaemia in the general community. 10 A unique or single transforming virus, 10 which has been noted in leukaemia in some animal species, has not been detected in acute lymphoblastic leukaemia. 21 Rather, the illness is prob ably promoted indirectly by an abnormal or dysregulated immune response to one or more common infections (viral or bacterial) in susceptible individuals. Infl uenza viruses are plausible candidates. 26 In such a scenario, susceptible children would have minimum previous exposure to infection during infancy, a persistent in-utero-generated preleukaemic clone, 10 and a variable degree of genetic susceptibility. Exploration of the possible biological mechanisms of infectious promotion should continue, 27 because it could lead to prophylactic interventions.
Inherited susceptibility
Very little evidence shows inherited predisposition via highly penetrant mutations in children or adults. 28 The high concordance in identical twin children has a nongenetic explanation (blood cell chimaerism). 9 Infants born with constitutive trisomy 21 or Down's syndrome are, however, at substantially increased risk of acute lympho blastic leukaemia (roughly 40 fold at age 0-4 years) and acute myeloid leukaemia. 29 The seeming absence of familial clustering of acute lymphoblastic leukaemia or greatly raised sibling risk (maximum 2 fold) does not, however, argue against inherited susceptibility. Previous attempts to identify inherited genetic susceptibility to the disease have been based on a candidate gene approach. Such studies 30 identifi ed some noteworthy potential candidates implicated in, for example, folate metabolism and the immune response, but most were statistically underpowered or not con sistently reproducible.
Genome-wide association studies of childhood acute lymphoblastic leukaemia compare the whole genome (usually remission-blood-derived DNA) in large series of patients to that in an ethnically matched control group and focus on single nucleotide polymorphisms in DNA sequences (with roughly 80% genome coverage). [31] [32] [33] These studies need hundreds or thousands of patients and controls, and, in view of the thousands of pangenome markers being compared, a p of less than 10 -⁷ is generally needed to deem the result robust. Genomewide association studies should be validated in a second, independent series of patients and independently confi rmed by another research group. So far, common allelic variants in IKZF1, ARID5B, CEBPE, and CDKN2A have been signifi cantly and consistently associated with childhood acute lymphoblastic leukaemia (appendix). [31] [32] [33] Variants in other genes probably have odds ratios (or impact) less than 1·2, but can be identifi ed only in very large cooperative studies (3000-5000 cases).
Gene variants have additive eff ects; someone inheriting one copy of a variant will have a roughly 50% increased risk whereas someone who inherits all four variants in homozygous form would have a roughly 10-fold increased risk. The overall conclusion from these studies is that the risk of childhood acute lymphoblastic leukaemia is aff ected by co-inheritance of several lowrisk variants. That the incidence of B lymphoblastic leukaemia with high hyperdiploidy is lower in AfricanAmerican children than in other children in the USA might partly be a result of lower prevalence of the ARID5B risk allele (appendix). 34 Inherited allelic variation might also aff ect response to treatment. 35 The products of the four genes implicated by genomewide association studies do not impinge directly on Figure 1 : Composite causality of childhood acute lymphoblastic leukaemia Exogenous (eg, infection) and endogenous (eg, infl ammation, oxidative stress) exposures, normal allelic variation in inherited genes, and chance all have roles in the covert natural history of childhood acute lymphoblastic leukaemia. [8] [9] [10] Cancer causation is closely linked with chance 11 -eg, incidental external exposure, damage to a relevant oncogene in a relevant cell (stem or progenitor cell), chance events at conception implicating parental gene shuffl ing and recombination. 
Hypothesis

Key notions Timing Agent Evidence
Kinlen population mixing hypothesis 18, 19 Unusual demographic mixing of susceptible and infected individuals Herd immunity 20 Animal leukaemia precedents 21 Possibly perinatal
Possibly a single novel virus
Transiently increased incidence (roughly double) in several situations of population mixing or clusters 19 Greaves delayed infection hypothesis 10, 22 Delayed exposure to common infections in childhood because of underexposure as infants Mismatch between evolutionary programming of immune system and modern (hygienic) lifestyle 10 Two-step prenatal and postnatal natural history 10 Late promotional or triggering event 10 One or (more probably) several common infections (bacterial or viral)
Reduced risk associated with day-care attendance in infancy 23, 34 
Pathobiology
Genetic basis
High-resolution profi ling of genetic alterations has transformed understanding of the genetic basis of acute lymphoblastic leukaemia. That most childhood cases harbour gross chromosomal alterations has been known for several decades (fi gure 2). 36 In B-cell disease, these alterations include high hyperdiploidy with non-random gain of at least fi ve chromosomes (including X, 4, 6, 10, 14, 17, 18, and 21); hypodiploidy with fewer than 44 chromosomes; and recurring translocations includ ing t(12;21)(p13;q22) encoding ETV6-RUNX1, t(1;19)(q23;p13) encoding TCF3-PBX1, t(9;22)(q34;q11) encod ing BCR-ABL1, rearrangement of MLL at 11q23 with a wide range of partner genes, and rearrangement of MYC into antigen receptor gene loci. Dysregulation of TAL1, TLX1, TLX3, and LYL1, particularly by rearrange ment into T-cell antigen receptor loci, often occurs in T lymphoblastic leukaemia. These changes are of key im portance in both pathogenesis and clinical management (fi gure 3).
Many chromosomal rearrangements disrupt genes that regulate normal haemopoiesis and lymphoid development (eg, RUNX1, ETV6), activate oncogenes (eg, MYC), or constitutively activate tyrosine kinases (eg, ABL1). Several are signifi cantly associated with outcomes, particularly in B-cell disease, and are used in risk stratifi cation. High hyperdiploidy and ETV6-RUNX1 rearrangement are associated with favourable outcome, whereas low hypodiploidy and MLL rearrangement (especially in infants and adults) are associated with poor prognosis in both children and adults.
However, many of these alterations alone do not induce leukaemia in experimental models, and no gross chromosomal alteration is noted in many cases, suggesting that additional submicroscopic genetic alter ations contribute to leukaemogenesis. High-resolution microarray profi ling of DNA copy number alterations (deletions and gains) and sequencing have led to identifi cation of several novel structural genetic alterations and sequence mutations (some of which are being investigated as prognostic markers or therapeutic targets) that defi ne new subtypes of 
ETV6-RUNX1 22%
Hyperdiploid (>50 chromosomes) 20%
Hypodiploid (<44 chromosomes) 1% disease, contribute to leukaemogenesis, and aff ect treatment responsiveness. [37] [38] [39] [40] [41] [42] Importantly, many sub types of acute lymphoblastic leukaemia are characterised by distinct constellations of structural genetic alterations that together drive establishment of the leukaemic clone.
Submicroscopic genetic alterations
More than 50 regions of recurring DNA copy number alteration have been identifi ed in acute lymphoblastic leukaemia. 37, 38, [43] [44] [45] [46] [47] Deletions are more common than is amplifi cation and are typically focal and often implicate only one gene. The nature and frequency of these alterations are associated with cell lineage and cytogenetic disease subtype. Notably, MLL-rearranged acute lymphoblastic leukaemia, which is typically aggressive and arises early in life, harbours, on average, roughly one additional genetic alteration per case, whereas diseases associatied with ETV6-RUNX1 and BCR-ABL1 trans locations manifest later in childhood and typically harbour between at least six and eight additional genetic alter ations. Many of the implicated genes encode regulators of lymphoid development or cell cycle, tumour sup pressors, or lymphoid signalling molecules (fi gure 3, table 2). The most frequently altered genes are trans criptional regulators of B-cell lymphoid develop ment (eg, PAX5, IKZF1, EBF1), which are aff ected in more than two-thirds of B-cell disease, and the CDKN2A/CDKN2B loci encoding the INK4/ARF tumour sup pressors, which are implicated in more than 80% of T-cell cases. Although understanding of sequence muta tions is incomplete, data show that several genes are changed by various mechanisms (including deletion or amplifi cation, sequence mutation, and translocation) that are highly gene-dependent-eg, structural alter ations are more common than are sequence mutations in PAX5 and IKZF1 in B-cell disease, whereas WT1, PHF6, and NOTCH1 are frequently targeted by sequence alteration in T-cell disease.
Several genetic alterations have well established roles in leukaemogenesis (eg, activating mutations in NOTCH1). The roles of many other genes remain unknown, partly because of the paucity of murine models that faithfully represent human acute lymphoblastic leukaemia. However, several alterations disrupt the activity of the encoded proteins in vitro or result in dominant negative activity, and loss-of-function mutations in PAX5 and IKZF1 accelerate the onset of B lymphoblastic leukaemia in murine models. 48 IKZF1 alterations include loss-of-function deletions of the entire locus, focal deletions resulting in expression of dominant negative IKZF1 alleles, and, less frequently, sequence mutations. Alteration is associated with increased risk of treatment failure and relapse in both BCR-ABL1-positive and BCR-ABL1-negative disease. Although testing for IKZF1 alterations at diagnosis has not yet been incorporated into frontline trials of acute lymphoblastic leukemia, it is being assessed in prospective clinical studies.
Novel subtypes
As much as 8% of childhood cases have CRLF2 rearrangement at pseudoautosomal region 1 of Xp/Yp (fi gure 2; table 2). CRLF2 encodes the receptor for thymic stromal lymphopoietin. 40, 41 Either rearrangement of CRLF2 into the immunoglobulin heavy chain locus at 14q32 or a focal deletion immediately upstream of the gene occurs, resulting in the novel fusions IGH@-CRLF2 and P2RY8-CRLF2, respectively. Both events dysregulate CRLF2 expres sion, leading to increased expression by lymphoblasts that might be detected by diagnostic immunopheno typing. Less common is a p.Phe232Cys mutation that results in receptor dimerisation.
53 CRLF2 rearrangement is particularly common (>50% of cases) in cases associated with Down's syndrome.
Roughly 50% of cases with CRLF2 rearrangement harbour concomitant activating mutations in JAK1 or JAK2 (table 2) . 40, 41, 54 Particularly in disease not associated with Down's syndrome, CRLF2 and JAK alterations are associated with deleterious IKZF1 alter ations and poor outcomes. 55 JAK mutations are located either at or near the active site of the JAK kinase domain or in the pseudokinase domains of JAK1 or 2, most commonly at p.Arg683 of JAK2. Importantly, the JAK2 mutations that are common in acute lymphoblastic leukaemia are distinct from those noted in myelo proliferative neoplasms. 56 Coexpression of CRLF2 and JAK mutant alleles transforms model cell lines and activates downstream JAK-STAT signalling, suggesting that these alterations are cotrans forming in B-cell disease. 41 In disease asso ciated with Down's syndrome, alterations of IKZF1, but not of CRLF2 or JAK2, were associated with poor prognosis. 57 10-12% of cases of B lymphoblastic leukaemia have a gene expression profi le similar to that of BCR-ABL1 disease but are BCR-ABL1 negative, frequently show IKZF1 alteration, and have poor outcomes (fi gure 2). 51, 52 As much as 50% of BCR-ABL1-like cases have CRLF2 rearrangements and JAK mutations. Next-gen eration sequencing, including transcriptome and whole-genome sequencing, has shown that the remaining cases harbour a diverse range of rearrangements, deletions, and sequence mutations that activate cytokine-receptor and kinase signalling (eg, those implicating ABL1, EPOR, IL7R, JAK2, and PDGFRB); several of these alterations transform in vitro and activate kinase signalling in primary leukaemic cells. 58 Intrachromosomal amplifi cation of chromosome 21 occurs in roughly 2% of cases of B lympho blastic leukaemia (fi gure 2), 59 and was originally defi ned by fl uorescence in-situ hybridisation as a gain of at least three copies of RUNX1. 60 Subsequent studies showed that the amplifi cation region is typically large and complex and often accompanied by deletion of the subtelomeric regions of chromosome 21. 61 The func tional consequences of the amplication are largely unknown, but identifi cation is important because this subtype is associated with poor outcomes with standard-risk regimens.
59,62
Genetics of relapse and clonal heterogeneity
Cytogenetic 63 and genomic profi ling of samples collected at diagnosis and relapse shows substantial changes in the nature of genetic alterations during the course of most cases and that relapse often arises from the emergence of a minor subclone with genetic alterations distinct from those of the predominant clone at diagnosis (fi gure 3). [64] [65] [66] In most cases, the relapse clone shares lesions with the predominant clone at diagnosis, suggesting a common preleukaemic origin, but other lesions are discordant. Sensitive assays specifi c for individual alterations show that the relapse clone is often present in low proportions at diagnosis, suggesting that relapse alterations confer resistance to treatment. Furthermore, several of the alterations that most often emerge at relapse are also associated with poor treatment outcomes when present at diagnosis-eg, deletions of IKZF1, CDKN2A/CDKN2B. Less frequently, the relapse clone seems identical or completely dissimilar to that at diagnosis. Similar fi ndings were noted in candidategene-sequencing studies of relapsed disease, which identifi ed enrichment of loss-of-function mutations of the transcriptional coactivator and acetyltransferase CREBBP (encoding CREB-binding protein) and TP53 (table 2, fi gure 3).
42,67,68
Genome sequencing
Next-generation sequencing enables comprehensive identifi cation of the genetic changes in leukaemia. Simultaneous sequencing of hundreds of thousands of nucleic acids (so-called massively parallel sequencing) might be used to identify sequence muta tions and structural variants in the encoding portion of the genome (exome sequencing), the transcriptome (mRNA sequencing), or the entire genome. In 187 cases of high-risk B lymphoblastic leukaemia, 120 candidate genes and pathways targeted by DNA copy number alterations were sequenced; a high frequency of alterations targeting B lymphoid development (68%), the TP53-RB1 tumour suppressor pathway (54%), Ras signalling (50%), and Janus kinases (11%), and recurring mutations in genes including ETV6, TBL1XR1, CREBBP, MUC4, ASMTL, and ADARB2 were identifi ed. 69 Early T-cell precursor acute lymphoblastic leukaemia is an aggressive leukaemia characterised by an immature immunophenotype reminiscent of the murine thymic early T-cell precursor, 70 aberrant expression of myeloid and stem cell markers, a distinct gene expression profi le, and dismal outcomes. 71 Wholegenome sequencing of 12 cases, and mutational-recurrence testing in an additional 94 patients with T lymphoblastic leu kaemia (52 of whom had the early T-cell precursor form) showed that three pathways frequently mutated in acute myeloid leukaemia were mutated at high frequency in early T-cell precursor disease 72 -specifi cally, inacti vating mutations targeting haemopoietic and lymphoid development (including GATA3, ETV6, RUNX1, and IKZF1), muta tions driving aberrant cytokine receptor and Ras signalling (NRAS, KRAS, FLT3, JAK1, JAK3, and IL7R), and deleterious mutations in chromatin-modi fying genes, most notably components of polycomb repressor complex 2 (EZH2, EED, and SUZ12). Polycomb repressor complex 2 normally mediates trimethyl ation of H3K27, resulting in transcriptional repression; thus, these mutations are predicted to derepress transcription. These results extend fi ndings of PHF6 mutations in T-cell disease, which were obtained by sequencing X chromosome genes and explained the increased incidence in men and boys. 73 Whole-genome sequencing of all subtypes is needed to identify all genetic alterations contributing to leukaemo genesis. Additionally, studies of the nature of non-coding genetic mutations and the interaction of genetic, epigenetic, and transcriptomic factors will be of great interest.
Diagnosis
Morphological identifi cation of lymphoblasts by microscopy and immunophenotypic assessment of lineage commit ment and developmental stage by fl ow cytometry are essential for diagnosis. 2 Chromosomal analysis still has an important role in the initial cyto genetic work-up. Reverse transcriptase PCR, fl uorescence in-situ hybrid isation or multiplex ligation-dependent probe ampli fi cation, and fl ow cytometry are used to identify leukaemia-specifi c translocations, submicro scopic chromo somal abnormalities, and cellular DNA content, respectively. When genome-wide analysis becomes time eff ective and cost eff ective, it might replace many diagnostic techniques. Tests that have prognostic and therapeutic implications are listed in the appendix.
Risk assignment Clinical and biological factors
Age (infant or ≥10 years old), presenting leucocyte count (≥50 × 10⁹/L), race (Hispanic or black), male sex, and T-cell immunophenotype are adverse clinical prognostic factors in children, although their eff ect is diminished by contemporary risk-adapted treatment and improved supportive care. [2] [3] [4] [5] [6] Infants with MLL rearrangements, especially those younger than 6 months old with more than 300 × 10⁹ leucocytes per L at diagnosis, still have a dismal prognosis. 7 Racial diff erences in prognosis have been linked not only to socioeconomic factors but also to diff erences in genomic variarions. 55, 74, 75 For example, germline single nucleotide polymorphisms of PDE4B and ARID5B are associated with Native American genetic ancestry, 74, 75 and somatic CRLF2 rearrangements in acute lymphoblastic leukaemia blasts 55 were over-represented in children from a Hispanic background; these alterations con tributed to inferior outcomes in Hispanic children. Adverse prognosis conferred by genetic ancestry was mitigated by adding a course of delayed intensifi cation therapy. 74 Adolescents and adults have a greater prevalence of biologically high-risk leukaemia (eg, BCR-ABL1, MLL rearrangement), a lower incidence of favourable subtypes (eg, ETV6-RUNX1, hyperdiploidy), and poorer adher ence to, and tolerance of, treatment than do pre-adolescent children. 76 Older age (especially ≥60 years) and high presenting leucocyte count are poor prognostic factors in adults (appendix). Adolescents and adults seem to have better outcomes with paediatric than with adult regimens. [76] [77] [78] [79] [80] Typically, paediatric regimens provide higher doses of non-myelosuppressive drugs, early and frequent intra thecal therapy, reinduction and long maintenance phases, and strict oversight of adherence.
Response to treatment
Early response is predictive of the risk of relapse and is used to assign patients to subsequent risk-adapted treatment. 81 Methods that track residual leukaemic cells by fl ow cytometry (for aberrant immunophenotypes) and PCR amplifi cation (for leukaemia-specifi c immunoglobulin and T-cell receptor genes or fusion transcripts) allow detection at proportions less than those de tectable by microscopic morphological assessment-ie, minimal residual disease (MRD). MRD is the most powerful prognostic indicator in childhood and adult disease, even in patients with low-risk features at presentation. 6, [82] [83] [84] [85] [86] The kinetics of MRD clearance in response to identical remission-induction chemotherapy diff ers between disease subtypes; negative MRD on day 33 (after administration of four drugs) was the strongest prognostic factor in B-cell disease, 83 whereas negative MRD on day 78 (after seven drugs) was also predictive in T-cell disease, irrespective of positive MRD status on day 33. 84 PCR is typically more sensitive than is fl ow cytometry for measurement of MRD (roughly 0·001% vs roughly 0·01%), and PCR-measurable low proportions of MRD (0·001-<0·01%) after remission-induction therapy have prognostic importance in children. 87 However, fl ow cytometry is faster, generally less expensive, and applicable to a larger proportion of patients, 81 allowing early tailoring of treatment. 85 The sensitivity of fl ow cytometry can be improved with multicolour combin ations of additional leukaemia-associated markers identifi ed from diff erently expressed genes in acute lymphoblastic leukaemia cells, yielding a detection threshold of roughly 0·001%.
88
Treatment
Treatment typically spans 2-2·5 years, and comprises three phases: induction of remission, intensifi cation (or consolidation), and continuation (or maintenance). 2 Most of the drugs used were developed before 1970. However, their dosages and schedule in combination chemotherapy have been optimised on the basis of leukaemic-cell biological features, response to treatment (MRD), and pharmacodynamic and pharmacogenomic fi ndings in patients, resulting in the high survival rate. CNS-directed treatment prevents relapse due to sequestered leukaemia cells. Allogeneic haemopoietic stem cell transplantation is an option for patients at very high risk. We focus on the most important advances during the past 5 years.
Remission-induction therapy
4-6 weeks of remission-induction therapy eradicates the initial leukaemic cell burden and restores normal haemopoiesis in 96-99% of children and 78-92% of adults with acute lymphoblastic leukaemia. [2] [3] [4] [5] Chemotherapy generally includes a glucocorticoid (prednisone or dexamethasone), vincristine, and asparaginase, with or without anthracycline. This regimen seems suffi cient for standard-risk disease when intensifi ed postremission treatment is given. Patients at high or very high risk receive four or more drugs.
Prednisone (or prednisolone, which is dose-equivalent) has traditionally been used, but dexamethasone is increasingly used. 89 However, the optimum doses and bioequivalence of these drugs are unclear. In prospective randomised trials, [90] [91] [92] [93] dexamethasone provided better control of CNS leukaemia than did prednisone, and, at a prednisone-to-dexamethasone dose ratio of less than 7 to 1, yielded better event-free survival, especially in children with T-cell disease who responded well to prednisone prephase treatment and children younger than 10 years with B-cell disease. However, when a higher dose of prednisolone (dose ratio>7:1) was used, the two drugs showed no diff erence in effi cacy. 94, 95 Glucocorticoids are associated with infection, osteonecrosis, fracture, psychosis, and myopathy; the incidence of such side-eff ects is generally higher with dexamethasone than with prednisone. Thus, highdose dexamethasone (eg, 10 mg/m² per day) is not recommended for adolescents with B lympho blastic leukaemia during remission-induc tion therapy. 96 Three preparations of asparaginase are available. One is derived from Escherichia coli and one from Erwinia caratovora; the third is a monoethoxypolyethylene glycol succinimidyl conjugate of E coli L-asparaginase (PEG-asparaginase). 97 These formulations have different half-lives (PEG-asparaginase>E-coli-derived>E-caratovora-derived), and maintenance of asparagine depletion by optimising dose intensity and schedule is crucial. PEG-asparaginase has largely replaced the native E coli product, because it provides at least 2 weeks of therapeutic activity after a single dose and induces antibodies less frequently. 98, 99 Native-E-coli-asparaginase and PEG-asparaginase activity could be inversely related to titres of anti-E-coli-asparaginase antibodies, although PEG-asparaginase was inhibited only at high titres. 100 Therefore, PEG-asparaginase might be used when antibody titres are low or intermediate, and E caratovora asparaginase when titres are high. Glucocorticoids and asparaginase have a noteworthy pharmacokinetic interaction. 101, 102 High systemic exposure to asparaginase was associated with high exposure to dexamethasone, presumably because of impaired hepatic synthesis of proteins implicated in dexamethasone clearance. Thus, anti-asparaginase antibodies can reduce exposure to both drugs and might increase relapse risk. 102 Patients with BCR-ABL1-positive disease have poor prognoses but benefi t from early treatment with tyrosinekinase inhibitors (eg, imatinib, dasatinib). When tyrosinekinase inhibitors are added to multidrug chemotherapy, complete remission rates are more than 90% and eventfree survival is superior to that in historical controls. 103, 104 Unlike imatinib, dasatinib targets both ABL1 and Src kinases; it also has more potent activity against BCR-ABL1, is active against imatinib-resistant BCR-ABL1 (except that with T315I mutation), and has better CNS penetration.
104-106
Intensifi cation (consolidation) therapy
Intensifi cation (consolidation) therapy is given after remission-induction treatment, and eradicates residual leukaemic cells. 2, 3 High-dose (ie, 1-8 g/m²) methotrexate with mercaptopurine is often given, as are frequent pulses of vincristine and glucocorticoids, uninterrupted asparaginase for 20-30 weeks, and reinduction therapy with drugs similar to those used during remissioninduction therapy.
The accumulation of the active metabolites of methotrexate-methotrexate polyglutamates (MTXPG 1-7 )-in leukaemic cells is associated with antileukaemic activity, which can be aff ected by somatic and germline genetic factors, dose and duration of methotrexate, and folinic acid rescue. Functional enzyme and somatic genetic studies show that MTXPG [1] [2] [3] [4] [5] [6] [7] accumulation varies widely between subtypes of acute lymphoblastic leukaemia. Accumulation is low in TCF3-PBX1, T-cell, and ETV6-RUNX1 disease (and thus patients might benefi t from high doses of methotrexate), and high in hyperdiploid B-cell disease, especially that with gain of chromosomes 18 or 10. [107] [108] [109] Germline single nucleotide polymorphisms of the organic anion transporter polypeptide SLCO1B1 are associated with high methotrexate clearance. 110, 111 In patients with high-risk disease high-dose methotrexate (ie, 5 g/m² every 14 days for four doses) and mercaptopurine were more eff ective than were escalating-dose methotrexate (ie, initial dose of 100 mg/m², increasing by 50 mg/m² every 10 days for fi ve doses) plus PEGasparaginase, and were not associated with increased acute toxic eff ects. 112 Duration of eff ective serum concentrations of methotrexate is important; accumu lation of MTXPG [1] [2] [3] [4] [5] [6] [7] was less with high-dose 4-h infusions than with high-dose 24-h infusions. 113 Folinic acid rescue is necessary after high-dose methotrexate; however, excessive use can counteract antileukaemic eff ects of methotrexate and increase the risk of relapse. 114 Reinduction therapy is a crucial element of protocols for acute lymphoblastic leukaemia. Intensifi ed reinduc tion therapy with vincristine and asparaginase improved the outcome of patients with high-risk disease. 115 However, an identical second reinduction cycle did not improve the outcome of patients with high-risk disease and a rapid marrow response to 7 days of induction therapy or those with standard-risk disease, suggesting that residual leukaemic clones after a course of reinduction therapy might represent intrinsic drug resistance. 115, 116 Whether a second reinduction cycle off ers benefi ts to patients with high-risk disease and a slow early response in the context of contemporary therapy is unclear. Osteonecrosis frequently occurs after reinduction therapy, especially in children aged 10 years or older. Alternate-week (10 mg/m² per day on days 0-6 and 14-20) rather than continuous (10 mg/m² per day on days 0-20) administration of dexamethasone signifi cantly reduced osteonecrosis despite delivering a higher cumulative dose.
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Continuation therapy
Continuation therapy typically lasts 2 years or longer and comprises mainly daily mercapto purine and weekly metho trexate with or without pulses of vincristine and dexamethasone. Mercaptopurine and tioguanine are structural analogues of hypoxanthine and guanine, respectively, and inhibit de-novo purine syn thesis. Although tioguanine forms the active-metabolite thio guanine nucleotides in fewer steps and is more cytotoxic in vitro to lymphoblasts than is mercaptopurine, random ised studies have not consistently shown im provements in event-free 118, 119 or overall 120 survival, and protracted doses of 40 mg/m² per day or more were associated with death during remission, veno-occlusive disease, portal hypertension, and thrombocytopenia. [118] [119] [120] Thus, mercaptopurine is preferred for continuation therapy.
TPMT catalyses S-methylation of thiopurines to inactive methylated metabolites. Patients with heterozygous or homozygous TPMT defi ciency become moderately to pronouncedly myelosuppressed when given thiopurines. 121 They can develop secondary malignant disease, especially at high doses (eg, mercaptopurine 75 mg/m² per day). 122 Adherence of less than 95% to planned mercaptopurine doses is associated with relapse. 123 Therefore, uninterrupted, pharmacogenetics-based mercapto purine dosing is important. 2 After thioguanine nucleotides are incorporated into DNA, DNA mismatch repair enzymes exert cytotoxic eff ects. Defi ciency of such enzymes (eg, MSH2) renders leukaemic cells thiopurine-resistant.
124 MSH2 expression was low or undetectable in roughly 11% of children with newly diagnosed acute lymphoblastic leukaemia due to partial or complete somatic deletion of genes that regulate MSH2 degradation (MTOR, HERC1, PRKCZ, and PIK3C2B).
124 These children had a high incidence of relapse.
Haemopoietic stem cell transplantation and cellular therapy
Allogeneic haemopoietic stem cell transplantation is an option for children with very-high-risk or persistent disease. 125 Contemporary protocols with high-resolution HLA typing, case-based conditioning, and improved supportive care have reduced relapse-related mortality, regimen-related toxic eff ects, and infection. 126, 127 Furthermore, leukaemia-free survival is not aff ected by the source of stem cells (matched related, matched unrelated, cord blood, or haploidentical donor). [127] [128] [129] In view of the development of disease detection and frontline therapies, indications for allogeneic haemopoietic stem cell transplantation should be reassessed continuously. MRD of 1 cell in 10 000 or more before transplantation is strongly associated with relapse, and new strategies are needed to reduce the disease burden before and after the procedure. 130, 131 Patients with BCR-ABL1-positive acute lymphoblastic leukaemia who go into remission after multidrug chemotherapy with ABL1 kinase inhibitors and young children (<6 years) with B-cell disease in delayed remission after induction failure can be treated without transplantation. 103, 104, 132 Is the procedure bene fi cial in infants? Its role, if any, is limited to a small high-risk group. 133, 134 Although haemopoietic stem cell transplantation during fi rst complete remission is a key element of treatment in many adult centres, the greater application of paediatric regimens in adult patients should decrease its use.
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CNS-directed therapy
Control of CNS disease is a key component of treatment. Prophylactic cranial irradiation (12-18 Gy) is eff ective, but its use has been reduced or eliminated to prevent acute neurotoxic eff ects, neurocognitive defi cits, endocrinopathies, secondary malignant disease, and excess late mortality. 135 In the St Jude Total XV and Dutch Childhood Oncology Group acute lymphoblastic leukaemia-9 protocols, 6 ,136 cranial irradiation is replaced by triple intrathecal chemotherapy with methotrexate, hydro cortisone, and cytarabine for all newly diagnosed patients. The 5 year cumulative risk of isolated CNS relapse was 2·7% with the St Jude and 2·6% with the Dutch Childhood Oncology Group protocol-ie, within the range achieved by prophylactic cranial irradiation (1·5-4·5%). Patients at high risk of CNS relapse-ie, those with any CNS disease (including leukaemia-cell contamination as a result of traumatic spinal tap) or with T-cell disease 6 -should be given intensifi ed intrathecal therapy during early remission-induction therapy. Cranial irradiation can be reserved only for salvage treatment, because the retrieval rate is high in patients with an isolated CNS relapse who did not receive irradiation with initial treatment. 6 In a randomised study in standard-risk acute lymphoblastic leukaemia, triple-drug intrathecal treatment reduced the frequency of CNS relapse compared with intrathecal methotrexate only, but was associated with increased risk of bone marrow and testicular relapse, possibly because systemic therapy was less intensive. 137 In the St Jude total XV protocol, not only excellent CNS outcomes but also excellent overall outcomes (5 year eventfree survival 85·6%, overall survival 93·5%) were achieved. 6 Because CNS and haematological relapses are competing events, systemic chemotherapy with high-dose methotrexate, intensive asparaginase, and dexa methasone, plus risk-based early intensive intrathecal chemotherapy, have substantial roles in prevention of CNS relapse.
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Remaining questions and future directions
Some subsets of acute lymphoblastic leukaemia still have an adverse prognosis. Further intensifi cation of available regimens is unlikely to substantially improve survival but will increase short-term and long-term adverse eff ects. Reduction of treatment intensity should be sought in patients at low risk. Studies of chronic health complications in long-term adult survivors will help to refi ne treatments, reducing the toxic eff ects of treatment. Functional genomics and proteomics will improve understanding of the epidemiology and patho genesis of individual cases, allowing targeted person alised medicine (appendix). Most epidemiologial and pathobiological studies have been developed for paediatric diseasethese should be expanded to adult patients.
Pharmacological inhibitors of Janus kinases (eg, ruxolitinib) are being investigated in childhood disease harbouring CRLF2 and JAK alterations. 39 Detailed preclinical studies in BCR-ABL1-like disease showed that the ABL1 and PDGFRB inhibitors imatinib and dasatinib are eff ective against acute lymphoblastic leukaemia cells with NUP214-ABL1 rearrangements and JAK inhibitors are eff ective against those with BCR-JAK2 or IL7R mutations; such cases might be candidates for targeted therapy. 58 DNA and histone methyltransferase inhibitors and histone deacetylase inhibitors might reactivate silenced tumour-suppressor genes or increase sensitivity to concomitant chemotherapy. Such drugs could be used in infants with MLL-rearranged disease, in whom aberrant DNA and histone methylation are frequently observed, 138, 139 and in patients with CREBBP mutations that encode histone acetyltransferase CREBbinding protein. 42 Mutations in early T-cell precursor acute lymphoblastic leukaemia are also noted in acute myeloid leukaemia, suggesting that treatments for acute myeloid leukaemia or drugs that target JAK signalling might be benefi cial. 72 Monoclonal antibodies to surface antigens such as CD19, CD20, CD22, and CD52 have been used in unconjugated form (eg, rituximab and epratuzumab), conjugated to immunotoxins or chemotherapeutic drugs (eg, moxetumo mab, inotuzumab ozogamicin), or in the form of bispecifi c antibodies (blinatumomab). 140 The incorporation of rituximab into the hyper-CVAD regimen (fractionated cyclophosphamide, vincristine, doxorubi cin, dexamethasone) seems to improve outcome in adults younger than 60 years with CD20-positive, BCR-ABL1-negative B lympho blastic leukaemia. 141 Blinatumomab, a bispecifi c, single-chain antibody to CD19 and CD3ε, recruits and activates CD3 eff ector cytotoxic T cells and is cytotoxic to CD19-expressing target cells bound to the other arm of the antibody; it was active against relapsed and refractory B lymphoblastic leukaemia in an adult phase 2 study. 142 Emerging evidence shows that newly diagnosed acute lymphoblastic leukaemia comprises several subclones and that chemoresistance is frequently driven by subpopulations harbouring genetic alterations that confer resistance. [64] [65] [66] Thus, eff orts should be made to identify patients at high risk of relapse through use of highly sensitive methods to detect these subpopulations at diagnosis. Treatment should target these subpopulations to improve the effi cacy of therapeutic regimens while reducing intensity.
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